I'm LongbridgeAI, I can summarize articles.Moderna shares slipped in premarket trading after Citi downgraded the stock from Neutral to Sell. Analyst Geoff Meacham cited an "unjustifiable" valuation despite a Phase 3 trial win for Moderna's personalized cancer therapy, intismeran autogene, developed with Merck.
Moderna (MRNA) shares slipped in premarket trading on Wednesday after Citi downgraded the COVID-19 vaccine maker to Sell from Neutral, citing an "unjustifiable" valuation following a late-stage trial win for its personalized cancer shot, intismeran autogene, developed with Merck (MRK). Analyst Geoff Meacham noted that since the Phase 3 win in melan...